ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
Rhea-AI Summary
ORIC (Nasdaq: ORIC) will present clinical data for enozertinib (ORIC-114) in previously treated patients with HER2 exon 20 mutant NSCLC at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
The poster (Presentation 981P) is scheduled for Friday, December 5, 2025, 5:15–6:15 p.m. SGT in a poster display session.
ORIC will host a related conference call and live webcast on Saturday, December 6, 2025 at 8:00 p.m. ET; live Q&A will require pre‑registration and the webcast replay will be available via ORIC’s investor website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – ORIC
In the Dec 1 session, ORIC declined 6.14%, reflecting a notable negative market reaction. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Clinical data update | Positive | -4.4% | Phase 1b enozertinib EGFR exon 20 data with strong systemic and CNS activity. |
| Dec 05 | Equity inducement grants | Neutral | -4.4% | Inducement stock options and RSUs granted to new non-executive employees. |
| Dec 05 | Clinical data update | Positive | -3.5% | Phase 1b HER2 exon 20 NSCLC enozertinib data with 100% disease control at 80 mg. |
| Dec 04 | Clinical data update | Positive | +3.8% | ESMO data showing robust systemic and CNS activity in EGFR atypical mutations. |
| Dec 03 | Conference presentation notice | Positive | +3.1% | Announcement of late-breaking oral enozertinib presentations and investor call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ORIC news around enozertinib has often been clinically positive, yet share reactions were mixed, with several data-heavy ESMO updates followed by negative one-day moves and only some announcements seeing aligned positive price action.
Over early December 2025, ORIC has been centered on enozertinib at the ESMO Asia Congress 2025. The company announced late-breaking oral presentations and then reported Phase 1b data in EGFR atypical and EGFR exon 20 NSCLC, plus separate HER2 exon 20 data, generally showing meaningful response rates and CNS activity. Despite these updates, the stock saw both positive and negative single-day moves. Alongside this, ORIC disclosed inducement equity grants and previously provided financial and pipeline updates, framing today’s poster notice as part of a broader, ongoing data roll-out rather than a standalone inflection.
Key Terms
phase 1b medical
her2 exon 20 medical
nsclc medical
her2 inhibitor medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC.
| Poster presentation details: | |
| Title: | Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant |
| EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20 | |
| Mutant NSCLC: Randomized Dose Optimization | |
| Presentation Number: | 981P |
| Session Type and Title: | Poster Display session and cocktail |
| Session Date & Time: | Friday, December 5, 2025; 5:15 – 6:15 p.m. SGT |
Full abstracts are available for public viewing via the ESMO Asia Congress website.
Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
